Hekto Healthcare has officially entered the pet healthcare market with the launch of a probiotic product for pets.
On September 7, Hekto Healthcare announced the release of 'De Simone Pet Probiotics' under its probiotic brand 'De Simone.'
The product features a proprietary formula called 'De Simone Formulation,' which combines eight strains of bacteria and contains 30 billion CFU of probiotics per packet. It is designed with a chicken flavor to appeal to both dogs and cats. The development process included palatability testing with 133 pets.
Kim Seok-jin, CEO of Hekto Healthcare, stated, "We aim to grow into a brand that helps pet owners consistently manage their pets' healthy daily lives."
The launch of this new product aligns with a broader trend in the industry. Daewoong Pharmaceutical is currently seeking approval for its dog atopic dermatitis treatment 'Flodicitinib' and diabetes treatment 'Enblopet.' Additionally, it has introduced a liver disease treatment called 'UDCA Jeong' under its own brand 'Daewoong Pet.'
Yuhan Corporation has expanded into specialized pet treatments with its nutritional supplement brand 'Willopet,' which includes a cognitive dysfunction treatment 'Zedacure' and an immuno-oncology drug 'Paxluridin-15.' Il Dong Pharmaceutical is also operating the 'Il Dong Pet' series, which includes probiotics and joint health products.
The industry's interest in the pet market is driven by rapid growth in market size.
According to Fortune Business Insights, the global pet healthcare market is projected to grow from $21.38 billion (approximately 30 trillion won) in 2025 to $38.87 billion (approximately 55 trillion won) by 2034, with an average annual growth rate of around 6%. The domestic market is also expected to expand to about 20 trillion won by 2032, according to estimates from the Ministry of Agriculture, Food and Rural Affairs.
On September 7, Hekto Healthcare announced the release of 'De Simone Pet Probiotics' under its probiotic brand 'De Simone.'
The product features a proprietary formula called 'De Simone Formulation,' which combines eight strains of bacteria and contains 30 billion CFU of probiotics per packet. It is designed with a chicken flavor to appeal to both dogs and cats. The development process included palatability testing with 133 pets.
Kim Seok-jin, CEO of Hekto Healthcare, stated, "We aim to grow into a brand that helps pet owners consistently manage their pets' healthy daily lives."
The launch of this new product aligns with a broader trend in the industry. Daewoong Pharmaceutical is currently seeking approval for its dog atopic dermatitis treatment 'Flodicitinib' and diabetes treatment 'Enblopet.' Additionally, it has introduced a liver disease treatment called 'UDCA Jeong' under its own brand 'Daewoong Pet.'
Yuhan Corporation has expanded into specialized pet treatments with its nutritional supplement brand 'Willopet,' which includes a cognitive dysfunction treatment 'Zedacure' and an immuno-oncology drug 'Paxluridin-15.' Il Dong Pharmaceutical is also operating the 'Il Dong Pet' series, which includes probiotics and joint health products.
The industry's interest in the pet market is driven by rapid growth in market size.
According to Fortune Business Insights, the global pet healthcare market is projected to grow from $21.38 billion (approximately 30 trillion won) in 2025 to $38.87 billion (approximately 55 trillion won) by 2034, with an average annual growth rate of around 6%. The domestic market is also expected to expand to about 20 trillion won by 2032, according to estimates from the Ministry of Agriculture, Food and Rural Affairs.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.